{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Triggiani V"],"pubmed_abstract":["<h4>Background</h4> Chronic heart failure (CHF) affects the health care system with high social and economic costs due to recurrent hospital admissions or frequent ambulatory reassessments. Subclinical hypothyroidism (SCH) is commonly observed in patients with CHF and negatively affects myocardial function and remodeling and, ultimately, increases the risk of hospitalizations and all-cause and cardiovascular (CV) mortality. The role of levothyroxine replacement on relevant CV outcomes in patients with SCH and CHF is unclear. <h4>Objective</h4> To assess the effect of levothyroxine (compared to placebo or no treatment) on the incidence of all-cause and CV mortality, major adverse CV events, and heart failure in patients with SCH and CHF. <h4>Methods</h4> PubMed/MEDLINE, Cochrane Library, an"],"journal":["Frontiers in endocrinology"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9706201"],"repository":["biostudies-literature"],"pubmed_title":["Effect of levothyroxine replacement therapy in patients with subclinical hypothyroidism and chronic heart failure: A systematic review"],"pmcid":["PMC9706201"],"pubmed_authors":["Lisco G","Triggiani V","Cittadini A"],"additional_accession":[]},"is_claimable":false,"name":"Effect of levothyroxine replacement therapy in patients with subclinical hypothyroidism and chronic heart failure: A systematic review","description":"<h4>Background</h4> Chronic heart failure (CHF) affects the health care system with high social and economic costs due to recurrent hospital admissions or frequent ambulatory reassessments. Subclinical hypothyroidism (SCH) is commonly observed in patients with CHF and negatively affects myocardial function and remodeling and, ultimately, increases the risk of hospitalizations and all-cause and cardiovascular (CV) mortality. The role of levothyroxine replacement on relevant CV outcomes in patients with SCH and CHF is unclear. <h4>Objective</h4> To assess the effect of levothyroxine (compared to placebo or no treatment) on the incidence of all-cause and CV mortality, major adverse CV events, and heart failure in patients with SCH and CHF. <h4>Methods</h4> PubMed/MEDLINE, Cochrane Library, an","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-26T09:41:44.465Z","creation":"2025-04-06T13:09:11.895Z"},"accession":"S-EPMC9706201","cross_references":{}}